Evidence map›Paper›PMID 37774064›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2023

P53, CK20, and FGFR3 Overexpression is Associated with the Characteristics of Urothelial Cell Carcinoma of the Bladder

Mojgan Asgari, Faezeh Firouzi, Maryam Abolhasani, Mohammad Bahadoram, Maedeh Barahman, Zahra Madjd, Mitra Mehrazam, Shakiba Hassanzadeh, Esma'il Akade

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 4 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Mojgan AsgariDepartment of Pathology, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-1345-9497
Faezeh FirouziDepartment of Pathology, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-4324-8500
Maryam AbolhasaniDepartment of Pathology, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1889-284X
Mohammad BahadoramDepartment of Neurology, School of Medicine, Musculoskeletal Rehabilitation Research Center, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.ORCID 0000-0002-7106-9799
Maedeh BarahmanDepartment of Radiation Oncology, Firoozgar Hospital, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences (IUMS), Tehran, Iran.ORCID 0000-0003-0660-0069
Zahra MadjdDepartment of Molecular Medicine, Oncopathology Research Center, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-7329-2583
Mitra MehrazamDepartment of Pathology, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-6686-2533
Shakiba HassanzadehNickan Research Institute, Isfahan, Iran.ORCID 0000-0002-5091-5191
Esma'il AkadeDepartment of Medical Virology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.ORCID 0000-0001-7722-0165
Iran University of Medical Sciences · IRAhvaz Jundishapur University of Medical Sciences · IRIsfahan Fertility and Infertility Center · IRUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this study was to investigate the association between the overexpression of tumor protein (P53), cytokeratin 20 (CK20), fibroblast growth factor receptor 3 (FGFR3), biomarkers and the grading, prognosis, heterogeneity, and relapse tendency of urothelial cell carcinomas (UCCs) of the bladder.

methodsA cross-sectional study was conducted using 413 samples of Iranian patients diagnosed with UCC of the bladder. The tissue microarray technique was used to evaluate the patterns of tumor tissue. Two pathologists scored tissue staining using a semi-quantitative scoring system.

resultsThe results showed that P53 was a predictor of a high-grade pattern (the area under the curve (AUC)=0.620) with a best cut-off value of 95.0 using the receiver operating characteristic (ROC) curve. CK20 was another predictor of a high-grade pattern (AUC=0.745) with a best cut-off value of 15. However, the overexpression of both biomarkers was not associated with a heterogeneous pattern and could not predict tumor-associated death or relapse. The heterogeneous (odds ratio (OR)=4.535, p-value=0.001) and non-papillary (OR= 6.363, p-value= 0.001) patterns were effective predictors of tumor recurrence among all baseline variables, including patient and tumor characteristics. FGFR3 was positive in all specimens and was not a valuable biomarker for differentiating patterns. None of the variables predicted tumor prognosis.

conclusionThe study findings indicate that the intensity and percentage of cell staining for P53 and CK20 in the UCC of the bladder can aid in differentiating the grading patterns. The tendency of tumor relapse can be predicted by demonstrating heterogeneous and non-papillary patterns.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsBiomarkers, TumorCross-Sectional StudiesHumansIranKeratin-20Neoplasm Recurrence, LocalReceptor, Fibroblast Growth Factor, Type 3Tumor Suppressor Protein p53Urinary BladderBiomarkers, TumorFGFR3 protein, humanKeratin-20KRT20 protein, humanReceptor, Fibroblast Growth Factor, Type 3TP53 protein, humanTumor Suppressor Protein p53BiomarkersBladderCancer diagnosisoncopathologyUrothelial cancer

Identifiers

PMID37774064
PMCPMC10762771
OpenAlexW4387164493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.